Cyclophosphamide is a nitrogen mustard used to treat lymphomas, myelomas, leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide.
- Mechanism
- Curator reviewed
Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
- Primary indication
- Cyclophosphamide for intravenous injection is indicated for the treatment of a number of malignancies, including: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary,...Curator reviewed · 24 structured indications
- Formula / weight
- C7H15Cl2N2O2P · 261.086 g/mol (avg)
- First approval
- Canada, 2002 · United States, 1959
- Also known as
- (±)-2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE MONOHYDRATE · (RS)-Cyclophosphamide · Ciclofosfamide · Cyclophosphanum · Cytophosphane
- Code names
- Asta B 518 · B-518 · NSC 26271 · RCRA Waste Number U058 · WR- 138719
- Brand names
Resolves to
CMSMOCZEIVJLDB-UHFFFAOYSA-NSMILESClCCN(CCCl)P1(=O)NCCCO1What you can answer from here — as of September 21, 2026
Which drugs share a target with Cyclophosphamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account